Group 1 - The core viewpoint emphasizes that promoting digital transformation in manufacturing is essential for building a strong manufacturing city and achieving high-quality industrial economic development [1] - The city has established a "1+N+X" mechanism to support digital transformation, which includes creating a new industrial smart platform, planning multiple industry platforms, and cultivating various application scenarios [1][2] - The government has issued policies to support high-quality development in manufacturing, with a focus on digital transformation initiatives [1][4] Group 2 - The city is actively advancing the construction of digital transformation service platforms, focusing on key industrial chains and clusters, and has initiated five provincial-level "industry brain" pilot projects [2] - A digital transformation assessment system for small and medium-sized enterprises has been launched, with 1,312 companies evaluated this year [2] - The "Chat City Enterprise Home" intelligent service system has been developed to provide one-stop services, including policy interpretation and supply-demand matching, with nearly 400 solutions and service products available [2] Group 3 - The city encourages collaboration between service providers and manufacturing enterprises to explore digital technology applications and has identified five pilot projects for industry-wide transformation [3] - The city is leveraging opportunities in "artificial intelligence + manufacturing" and has successfully selected five projects for provincial-level industry model initiatives [3] - Several companies have been recognized for their digital transformation achievements, including Dong'e Ejiao Co., Ltd., which was named a "digital leader" by the Ministry of Industry and Information Technology [3] Group 4 - A comprehensive policy framework has been established to stimulate enterprise transformation, including action plans and funding support totaling nearly 280 million yuan since 2022 [4] - The policies cover various aspects such as technological upgrades, platform construction, and exemplary cases to ensure effective implementation [4] - Specific financial incentives have been introduced to support enterprises in areas like industrial internet platforms and smart factories, encouraging active participation in these initiatives [4]

Core Viewpoint - Dong'e Ejiao announced a revenue of 3.051 billion yuan for the first half of 2025, representing a year-on-year growth of 11.02% [1] - The net profit attributable to shareholders reached 818 million yuan, with a year-on-year increase of 10.74% [1] - The net profit after deducting non-recurring gains and losses was 788 million yuan, showing a year-on-year growth of 12.58% [1]

智通财经APP讯，华润医药(03320)发布公告，东阿阿胶公布其截至2025年6月30日止6个月的半年度报 告，该公司取得营业总收入人民币30.51亿元，同比增加11.02%;上市公司股东应占净利润8.18亿元，同 比增加10.74%;每股基本盈利1.27元。拟每10股分配现金股息人民币12.69元(含税)。 ...

东阿阿胶8月21日晚间公告，董事会同意，公司通过进场摘牌方式以自有资金预计3379.852万元收购东 丰城市发展投资（集团）有限公司（下称"城发集团"）持有的东丰马记药业有限公司（下称"马记药 业"）70%股权。收购完成后，公司将持有马记药业70%股权，城发集团将持有马记药业30%股权。本次 交易完成后，马记药业将成为公司控股子公司，纳入合并报表范围。本次交易目前处于挂牌转让阶段， 尚未签署合同，协议内容和具体操作方式以各方最终签署的正式协议为准。 ...

Group 1 - The company announced a donation of 4.3 million yuan to the China Women's Development Foundation, which includes a cash donation of 2.6 million yuan and in-kind donations valued at 1.7 million yuan [1] - The purpose of the donation is to support the Healthy China initiative and rural revitalization strategy, aiming to improve the medical environment for grassroots citizens and enhance the company's visibility and reputation [1] - The donation does not involve related party transactions and does not constitute a major asset restructuring, having no significant impact on the company's financial status and operating results [1]

Core Viewpoint - Dong'e Ejiao reported a revenue of 3.051 billion yuan for the first half of 2025, representing a year-on-year growth of 11.02% [1] - The net profit for the same period was 818 million yuan, showing a year-on-year increase of 10.74% [1] - The company plans to distribute a cash dividend of 12.69 yuan (including tax) for every 10 shares to all shareholders [1] Financial Performance - Revenue for the first half of 2025: 3.051 billion yuan, up 11.02% year-on-year [1] - Net profit for the first half of 2025: 818 million yuan, up 10.74% year-on-year [1] Dividend Announcement - Proposed cash dividend: 12.69 yuan per 10 shares (including tax) [1]

东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十一次会议，审议通过了《关于对外捐赠的议案》。现将有关情况 公告如下： 一、对外捐赠事项概述 为积极响应健康中国建设以及乡村振兴战略号召，支持华润健康乡村公益项 目，同时提升公司知名度与美誉度、彰显国企责任与担当，公司拟向中国妇女发 展基金会捐赠 430 万元，其中包括资金捐赠 260 万元以及实物捐赠价值 170 万元。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本议案经董事 会审议通过后即可实施，无需提交股东大会审议。 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-49 东阿阿胶股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 董 事 会 二〇二五年八月二十二日 1．第十一届董事会第十一次会议决议； 2．深交所要求的其他文件。 本次捐赠事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 二、对公司的影响 本次对外捐赠持续落实健康中国建设和乡村振兴战略，旨在进一步改善 ...

| 控股股东、实际控制人 | 华润科伦医药(四 | 同一控股股东 | 应收账款 | 4,256.39 | 4,256.39 | | 销售货物 | 经营性往 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 及其附属企业 | 川)有限公司 | | | | | | | 来 | | 控股股东、实际控制人 | 华润昆明医药有限 | 同一控股股东 | 应收账款 | 3.88 | 3.88 | | 销售货物 | 经营性 | | 及其附属企业 | 公司 | | | | | | | 往来 | | 控股股东、实际控制人 | 华润河北医药有限 | 同一控股股东 | 应收账款 | 288.99 | 288.99 | | 销售货物 | 经营性往 | | 及其附属企业 | 公司 | | | | | | | 来 | | 控股股东、实际控制人 | 华润医药商业(陕 | 同一控股股东 | 应收账款 | 65.01 | 65.01 | | 销售货物 | 经营性往 | | 及其附属企业 | 西)有限公司 | | | | | | | 来 | | 控股股东、实际控制人 | 华润医 ...

东阿阿胶股份有限公司 2025 年半年度财务报告 东阿阿胶股份有限公司 东阿阿胶股份有限公司 2025 年半年度财务报告 财务报告 中期财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 2025 年 1 月 1 日至 2025 年 6 月 30 日止 1 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：东阿阿胶股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 6,628,575,237.00 | 5,014,911,161.46 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 2,110,250,180.88 | 3,519,212,876.21 | | 衍生金融资产 | | | | 应收票据 | 15,207,177.91 | 255,522,711.76 | | 应收账款 | 184,780,862.62 | 79,198,661.27 | | 应收款项融资 | 61,391, ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-46 东阿阿胶股份有限公司 第十一届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 3．会议应出席会议监事 5 人，实际出席会议监事 5 人。 4．本次监事会会议，由监事会主席周娇女士主持。 5．本次监事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、监事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于 2025 年半年度报告及摘要的议案》 经审议，公司《2025 年半年度报告全文及其摘要》的编制，符合法律法规、 中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。公司实际经营情况，不存在任何虚假记载、误导性陈述 或重大遗漏。公司《2025 年半年度报告全文及其摘要》是按照中国证监会和深 圳证券交易所颁发的信息披露内容与格式准则等有关要求编制的，所包含内容真 1．东阿阿胶股份有限公司（以下 ...